McKesson Corporation
MCK
$822.63
-1.48%
McKesson Corporation is a dominant player in the healthcare supply chain, primarily operating as one of the three leading pharmaceutical wholesalers in the United States, sourcing and distributing branded, generic, and specialty drugs to pharmacies, hospitals, and healthcare providers. The company's competitive identity is that of a critical infrastructure provider within the oligopolistic US pharmaceutical distribution market, where it, along with Cencora and Cardinal Health, controls over 90% of the wholesale industry, complemented by its medical-surgical distribution and healthcare technology solutions. The current investor narrative centers on the company's ability to deliver consistent, low-single-digit revenue growth and robust cash flows from its stable core distribution business, while also navigating the ongoing integration and performance of its higher-margin Prescription Technology Solutions and Oncology segments, which are key drivers for margin expansion and valuation re-rating.…
MCK
McKesson Corporation
$822.63
Investment Opinion: Should I buy MCK Today?
Rating & Thesis: Hold. McKesson is a high-quality, cash-generative infrastructure stock trading at a fair forward valuation, but near-term technical weakness and a premium trailing multiple suggest waiting for a better entry point or clearer confirmation of resumed uptrend. The lack of a clear analyst consensus complicates the view, but the fundamental picture supports a stable, income-generating holding.
Supporting Evidence: The recommendation is backed by four key data points: 1) A forward PE of 18.77x is below the industry average of 22x, suggesting fair forward valuation. 2) Revenue growth remains solid at 11.4% YoY. 3) Operating margin improved sequentially from 1.42% to 1.52%, demonstrating positive trajectory. 4) Exceptional TTM FCF of $10.10B provides a margin of safety and fuels shareholder returns. However, the trailing PE premium of 26.02x and the stock's position at 83% of its 52-week range after a sharp pullback temper enthusiasm.
Risks & Conditions: The two biggest risks are multiple compression from its premium trailing valuation and a deceleration in the margin expansion trend. This Hold rating would upgrade to a Buy if the stock convincingly breaks above its recent consolidation resistance near $870, signaling a resumption of the uptrend, or if the forward PE compresses further towards 17x. It would downgrade to Sell if quarterly revenue growth falls below 5% or operating margins contract sequentially. The stock is currently fairly valued on a forward basis but carries a premium on a trailing basis, implying the market expects continued successful execution.
Sign up to view all
MCK 12-Month Price Forecast
McKesson's fundamentals are strong and defensive, supported by its oligopoly position and immense cash flow. However, the investment case is currently in a 'show me' phase. The stock's premium trailing valuation and recent sharp pullback indicate the market is questioning the pace of its transformation. The neutral stance reflects this tension between solid long-term fundamentals and near-term technical and valuation headwinds. Confidence is medium due to the limited analyst coverage, which reduces visibility. The stance would turn bullish on a confirmed technical breakout above $950 or bearish on a breakdown below $800 with deteriorating margins.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $1069.42 and implied upside of +30.0% versus the current price.
Average Target
$1069.42
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$658 - $1069
Analyst target range
Analyst coverage appears limited in the provided dataset, with only one analyst providing estimates for EPS and revenue, which is insufficient to derive a meaningful consensus recommendation or target price distribution. This minimal coverage is unusual for a company of McKesson's size and may indicate data gaps, but typically limited coverage can lead to higher volatility and less efficient price discovery as the stock is less scrutinized by the institutional investment community. The single analyst's revenue estimate for the period averages $551.3 billion, and the EPS estimate averages $66.15, but without a consensus price target or rating spread, it is impossible to gauge the bullish or bearish sentiment or the range of potential outcomes assumed by the Street; investors should seek more comprehensive coverage data to understand the prevailing institutional view on the stock's fair value.
Bulls vs Bears: MCK Investment Factors
The evidence presents a balanced but cautiously optimistic picture. The bull case is stronger on fundamental grounds, anchored by McKesson's unassailable market position, robust cash generation, and improving profitability. However, the bear case holds sway in the near term due to clear technical deterioration and a valuation that, while reasonable forward, carries a premium on a trailing basis. The single most important tension in the investment debate is whether the company's strategic initiatives in Prescription Technology Solutions and Oncology can successfully drive margin expansion sufficient to justify and sustain its current valuation premium, or if the stock reverts to its historical lower-multiple range as a pure distributor.
Bullish
- Dominant Market Position & Stable Cash Flows: McKesson operates in an oligopolistic market, controlling over 90% of US pharmaceutical wholesale alongside two peers, providing a stable, high-volume revenue base. This is evidenced by massive trailing twelve-month free cash flow of $10.10 billion, funding consistent shareholder returns.
- Strong Revenue & Margin Growth Trajectory: Recent quarterly revenue grew 11.4% YoY to $106.16B, with sequential acceleration. More importantly, operating margin improved to 1.52% from 1.42% in the prior quarter, indicating successful execution and cost management driving bottom-line expansion.
- Attractive Forward Valuation: The forward PE of 18.77x is significantly below the trailing PE of 26.02x, pricing in substantial earnings growth. This forward multiple is also below the inferred industry average PE of 22x, suggesting the stock is not overvalued relative to peers on a forward basis.
- Low Market Volatility Profile: With a beta of 0.423, the stock has historically been 58% less volatile than the broader market. This characteristic provides downside cushion during turbulent periods, as seen in its shallower drawdowns relative to the SPY.
Bearish
- Significant Pullback & Negative Momentum: The stock is down -5.87% over the past month and shows severe relative weakness versus the SPY at -14.57, indicating weakening near-term sentiment. It trades at $828, well below its 52-week high of $999, suggesting the prior uptrend has stalled.
- Premium Trailing Valuation: The trailing PE of 26.02x trades at an 18% premium to the industry average of 22x. This premium valuation leaves the stock vulnerable to multiple compression if growth expectations are not met, especially given its recent price decline.
- Inherently Thin Operating Margins: As a distribution business, McKesson operates on razor-thin margins, with a gross margin of 3.47% and operating margin of 1.52%. This leaves little room for operational error and makes earnings highly sensitive to cost inflation or pricing pressure.
- Limited Analyst Coverage & Visibility: The provided dataset shows coverage from only one analyst, which is unusually low for a company of this size. This lack of scrutiny can lead to less efficient price discovery and higher volatility due to unexpected earnings surprises.
MCK Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a 1-year price change of +20.29%, but is currently experiencing a significant pullback from recent highs, trading at approximately $828, which is 83% of its 52-week range ($637 to $999). This positioning near the upper end of the range, but well off the peak, suggests the momentum from the prior uptrend has stalled, potentially indicating a period of consolidation or profit-taking after a strong run. Recent momentum has turned decisively negative, with the stock down -5.87% over the past month and up a modest +0.96% over three months, a sharp deceleration from the 1-year trend; this divergence, coupled with a severe -14.57 relative strength versus the SPY over one month, signals weakening near-term sentiment and underperformance likely driven by broader market rotations or sector-specific concerns. Key technical levels are clearly defined by the 52-week high of $999 as major resistance and the 52-week low of $637 as support; a decisive break above resistance would signal a resumption of the powerful uptrend, while a breakdown below the recent consolidation range could target the $800 area, with the stock's low beta of 0.423 indicating it has been significantly less volatile than the broader market, which may provide some downside cushion during turbulent periods.
Beta
0.42
0.42x market volatility
Max Drawdown
-17.4%
Largest decline past year
52-Week Range
$637-$999
Price range past year
Annual Return
+16.3%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | +12.6% |
| 3m | +0.0% | +2.5% |
| 6m | +1.4% | +4.3% |
| 1y | +16.3% | +28.4% |
| ytd | -0.1% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
Revenue growth remains steady, with the most recent quarterly revenue of $106.16 billion representing a solid 11.4% year-over-year increase, and the sequential trend from the prior quarter's $103.15 billion shows continued acceleration; the North American Pharmaceutical Segment, at $88.32 billion, is the dominant growth driver, while the Prescription Technology Solutions and Oncology segments represent higher-margin, strategic growth avenues. Profitability is robust, with net income of $1.19 billion and a gross margin of 3.47% for the quarter, though the gross margin is characteristically thin for a distribution business; operating income of $1.62 billion and an operating margin of 1.52% have improved sequentially from 1.42% in the prior quarter, indicating effective cost management and a positive trajectory for bottom-line expansion. The balance sheet and cash flow position is exceptionally strong, highlighted by trailing twelve-month free cash flow of $10.10 billion, a current ratio of 0.90 indicating sufficient short-term liquidity, and a negative Return on Equity (-158.87%) and Debt-to-Equity (-3.56) that are distorted by accounting treatment of equity but do not impair the company's ability to consistently generate massive cash flows, which fund substantial shareholder returns through buybacks and a modest dividend.
Quarterly Revenue
$106.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$10.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 26.02x, while the forward PE is notably lower at 18.77x, indicating the market is pricing in significant earnings growth over the next twelve months. Compared to the provided industry average PE of 22x (inferred as a typical sector benchmark), McKesson's trailing multiple trades at an 18% premium, which is likely justified by its market-leading position, consistent execution, and superior cash flow generation relative to peers. Historically, the stock's own PE ratio has fluctuated significantly, with the current trailing multiple of 26.02x sitting above its recent historical average seen in the data (e.g., 21.30x in Q3 2026, 15.48x in Q4 2023), suggesting the market is currently valuing the company at a relatively optimistic level, pricing in successful execution of its strategic initiatives and sustained margin improvement.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1346x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: McKesson's primary financial risk is not liquidity or solvency—its $10.1B TTM FCF is formidable—but rather the sustainability of its margin expansion narrative. Operating margins, while improving sequentially to 1.52%, remain exceptionally thin. A reversion to the 1.42% level seen last quarter would significantly impact net income on its massive revenue base. Furthermore, the company's negative ROE and D/E ratios, while accounting distortions, highlight a capital structure that relies on consistent, high-volume cash flow generation to support shareholder returns, making it sensitive to any disruption in its core distribution throughput.
Market & Competitive Risks: The stock faces clear valuation compression risk. Its trailing PE of 26.02x represents an 18% premium to the industry average. If growth decelerates or margin expansion stalls, a derating towards the sector multiple could imply meaningful downside. Competitive risks are moderated by the oligopolistic industry structure, but regulatory headwinds targeting drug pricing or supply chain middlemen pose an external threat. The stock's low beta of 0.423 suggests it is less correlated to broad market swings, but its recent severe underperformance (-14.57 RSI vs. SPY) indicates it is susceptible to sector-specific rotations out of healthcare or value stocks.
Worst-Case Scenario: The most damaging scenario would involve a simultaneous earnings miss, guiding down future margin expansion expectations, triggering multiple compression. This could be exacerbated by a broader market downturn. In this adverse scenario, the stock could realistically fall to its 52-week low of $637, representing a -23% decline from the current price of $828. A more measured bear case, aligning with a reversion to its historical average PE multiple, would still imply a double-digit drawdown. The key risk is the market losing faith in the 'story' of margin improvement, recasting MCK as a low-growth, low-margin utility.
FAQ
The key risks are, in order of severity: 1) Valuation Compression: The 18% trailing PE premium could evaporate if growth slows (Trailing PE: 26.02x vs. Industry: 22x). 2) Margin Pressure: The business operates on inherently thin margins (Op Margin: 1.52%); cost inflation could directly hit profits. 3) Execution Risk: The company's future valuation relies on successful growth in higher-margin segments like Prescription Technology Solutions. 4) Regulatory & Macro: Changes in drug pricing policy or a recession impacting healthcare spending could disrupt the stable distribution volume.
The 12-month forecast for MCK is a range-bound outlook with a neutral bias. The base case (60% probability) sees the stock trading between $850 and $950, as steady execution supports its current forward valuation. The bull case (25%) targets $990 to $1050+ if margin expansion accelerates, leading to a re-rating. The bear case (15%) warns of a drop to the $637-$800 range if the growth narrative falters and multiples compress. The most likely scenario is the base case, assuming the company meets, but does not exceed, current margin improvement expectations.
MCK's valuation presents a mixed picture. On a trailing basis, its PE of 26.02x is at an 18% premium to the industry average of 22x, suggesting it is overvalued if growth stalls. However, its forward PE of 18.77x is below that same average, implying it is fairly valued or even slightly undervalued based on expected earnings growth. The market is currently paying a premium that prices in successful execution of margin expansion initiatives. If those initiatives deliver, the current forward multiple is justified; if they falter, the stock is vulnerable to derating.
MCK is a good buy for patient, long-term investors seeking a defensive holding with robust cash flow, but timing is crucial. At its current forward PE of 18.77x, it is fairly valued relative to its growth and sector. The massive $10.1B annual free cash flow provides a strong foundation. However, given the recent -5.87% monthly decline and negative momentum, it may be prudent to wait for the technical picture to stabilize, perhaps on a pullback closer to $800, before establishing a full position. It is less suitable for short-term traders.
MCK is unequivocally suitable for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta of 0.423 indicates low volatility relative to the market, making it a poor candidate for short-term trading which thrives on volatility. The investment thesis is based on the gradual execution of a strategic shift and the compounding effect of consistent share repurchases funded by massive FCF. Short-term price movements are likely to be driven by sentiment and technicals, while the long-term value will be driven by the durability of its cash flows and its success in improving profitability.